Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off viruses. Bamlanivimab is a monoclonal antibody specifically designed to block the COVID-19 virus’ attachment and entry into human cells.
Patients receive the treatment through an hour-long infusion, followed by observation for an hour to monitor for any possible symptoms, which could include nausea, diarrhea, dizziness, headache, itching and vomiting.
Metcalfe said she didn’t experience any symptoms from the treatment; very few side effects have occurred in individuals receiving the treatment. She continued to have fatigue and cold-like symptoms from COVID-19 for a couple of days, but she didn’t get worse.
“The possible side effects meant nothing to me, because I knew what would happen if I did get COVID-19,” she said. “I got blessed by this infusion.”